Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3151 - Molecular subtyping of breast cancer by dedicated breast PET

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Satoshi Sueoka

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

S. Sueoka, S. Sasada, E. Suzuki, N. Goda, K. Kajitani, A. Emi, N. Masumoto, T. Kadoya, R. Haruta, T. Kataoka, M. Okada

Author affiliations

  • Breast Surgery, Hiroshima University Hospital, 734-8551 - Hiroshima/JP
More

Resources

Abstract 3151

Background

Therapeutic strategies for treating breast cancer differ according to molecular subtype. We investigated whether dedicated breast PET (DbPET), a high-resolution molecular breast imaging system, could stratify breast cancer by subtype.

Methods

We included 390 patients with invasive breast cancer who underwent ring-type DbPET between January 2016 and March 2018. The association between SUVmax and various tumor characteristics such as size, nuclear grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and Ki-67 labeling index, were assessed. Tumor subtypes were classified as luminal A-like, luminal B-like, ER+/HER2+, ER-/HER2+, or triple negative on the basis of the St. Gallen International Expert Consensus.

Results

The median patient age was 57 years, the median tumor size was 1.5 cm, and the median SUVmax on DbPET was 6.9. The number of patients with each subtype was luminal A-like in 113, luminal B-like in 185, ER+/HER2+ in 40, and ER-/HER2+ in 12, and triple negative in 40 patients. SUVmax significantly correlated with tumor size (P < 0.001), nuclear grade (P < 0.001), ER status (P = 0.004), HER2 status (P < 0.001), and Ki-67 labeling index (P < 0.001). The median SUVmax values of the luminal A-like, luminal B-like, ER+/HER2+, ER-/HER2+, and triple negative subtypes were 4.6, 8.2, 9.5, 16.1, and 10.4, respectively (Table, all values of P < 0.001 relative to luminal A-like). Thus, DbPET distinguished luminal A-like tumor subtype from other subtypes.Table: 203P

SUVmax on dedicated breast PET according to molecular subtypes.
SubtypesMedian SUVmax (IQR)P value reffered to luminal A-like
Luminal A-like4.6 (3.0-6.8)
Luminal B-like8.2 (4.6-12.4)< 0.001
ER+/HER2+9.5 (5.5-16.6)< 0.001
ER-/HER2+16.1 (7.5-20.2)< 0.001
Triple negative10.4 (4.2-17.0)< 0.001

Conclusions

DbPET can be used to classify breast cancer into molecular subtypes, which may help determine the necessity of adjuvant chemotherapy. SUVmax, as assessed on DbPET, may thus contribute to the selection of proper therapeutic strategies in invasive breast cancer.

Clinical trial identification

Legal entity responsible for the study

Hiroshima University Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings